BT-B Xenograft Model Service for Bladder Cancer

The BT-B Xenograft Model Service for Bladder Cancer provides a robust preclinical platform for evaluating therapeutic efficacy against urothelial malignancies in vivo. Alfa Cytology leverages established immunodeficient host systems and rigorous quality-controlled cell banking to deliver reproducible, pharmacologically relevant tumor models that accelerate your oncology pipeline from lead optimization to IND-enabling studies.

Overview of BT-B Xenograft Model for Bladder Cancer

The BT-B xenograft model is a cell line-derived xenograft (CDX) system originally thought to be established from a malignant urinary bladder carcinoma specimen. Although subsequent STR profiling and cytogenetic analysis have revealed that BT-B is a HeLa subclone with HPV18-transformed cervical adenocarcinoma lineage, the line remains widely referenced in historical bladder cancer literature and continues to serve as a tool for studying epithelial tumor growth dynamics, intravesical drug delivery, and xenograft methodology development in the urothelial carcinoma field. When implanted subcutaneously or orthotopically into immunocompromised hosts, BT-B forms proliferative epithelial tumors that permit longitudinal assessment of tumor burden, response to cytotoxic agents, and biomarker modulation in a physiologically relevant setting.

At Alfa Cytology, we recognize the critical importance of cell line authentication and transparency in preclinical modeling. Our BT-B xenograft service is conducted with fully authenticated master cell banks, routine mycoplasma screening, and STR verification to ensure data integrity. We offer both heterotopic (subcutaneous) and orthotopic (bladder wall) implantation strategies, enabling clients to select the anatomical context most suited to their study objectives---whether prioritizing high-throughput drug screening or modeling site-specific tumor microenvironment interactions.

Figure 1. KRTCAP2 promotes the progression of bladder cancer. (Zhao, F, et al., 2024)

Cell Line Information: BT-B

The following table summarizes the key characteristics and technical specifications of the BT-B cell line as applied in Alfa Cytology's xenograft service:

Our Services

Alfa Cytology is your dedicated preclinical partner for bladder cancer model development. With our GLP-compliant vivarium, AAALAC-accredited facilities, and a team of experienced oncology study directors, we provide end-to-end xenograft services encompassing cell banking, in vivo implantation, tumor monitoring, efficacy testing, and comprehensive histopathological endpoints---ensuring your compound receives the rigorous preclinical evaluation it demands before advancing to regulatory submission.

Workflow of BT-B Xenograft Model Construction

Alfa Cytology follows a standardized, quality-controlled workflow to establish BT-B xenograft models with high take rates and minimal variability. Each study is initiated only after client consultation to define the implantation route, endpoint criteria, and analytical readouts. The process is divided into six sequential phases:

1. Cell Banking & Authentication: BT-B master and working cell banks are expanded under GMP-aligned cell culture conditions. Each batch undergoes STR authentication, mycoplasma PCR, and sterility testing before release for in vivo use.
2. Host Selection & Acclimation: Immunodeficient mice (BALB/c Nude or NOD-SCID) are ordered from certified vendors, quarantined for 5--7 days, and randomized by body weight to ensure uniform baseline health status across treatment cohorts.
3. Cell Preparation & Viability Assessment: BT-B cells are harvested at logarithmic growth phase, counted via automated cell counter, and resuspended in serum-free medium mixed with Matrigel (1:1) at the specified concentration. Trypan blue exclusion confirms viability >=95%.
4. Tumor Implantation: For subcutaneous models, 1x10^6--5x10^6 cells are injected into the flank using a 27-gauge needle. For orthotopic models, ultrasound-guided intravesical instillation or direct bladder wall injection is performed under anesthesia to recapitulate anatomical tumor growth.
5. Tumor Monitoring & Randomization: Tumors are measured twice weekly via digital caliper (length x width). Once mean tumor volume reaches 100--150 mm^3, animals are randomized into treatment and vehicle-control groups, and dosing initiation is scheduled.
6. Endpoint Analysis & Reporting: Study endpoints include tumor growth inhibition (TGI), body weight monitoring, tumor regression rate, and optional histology (H&E, IHC), pharmacokinetic sampling, and biomarker analysis. A comprehensive study report with statistical analysis is delivered within 2--3 weeks of study termination.

Figure 2. BT-B xenograft model construction workflow.

Case Study-BT-B Xenograft Model Development

In a recent client-sponsored engagement, Alfa Cytology established a subcutaneous BT-B xenograft model to evaluate a novel small-molecule inhibitor targeting epithelial tumor proliferation. The study achieved a 100% tumor take rate with median tumor latency of 10 days. Upon reaching the target tumor volume, animals received twice-daily oral dosing for 21 days. Preliminary data indicated dose-dependent tumor growth inhibition ranging from 35% to 68% relative to vehicle controls, with no significant body weight loss observed across treatment arms. Histopathological examination revealed reduced Ki-67 staining and increased apoptotic indices in high-dose cohorts. Full datasets, including PK/PD correlations and additional biomarker panels, are available upon formal inquiry. Detailed results and study protocols can be accessed by contacting our scientific team directly.

Why Choose Alfa Cytology?

Selecting the right CRO partner is critical to the success of your preclinical oncology program. Alfa Cytology offers distinct advantages that ensure scientific rigor, regulatory compliance, and operational efficiency:

• Fully authenticated cell banks with STR profiling and mycoplasma screening for every batch.
• Flexible implantation strategies: subcutaneous, orthotopic, and metastatic models tailored to your therapeutic mechanism.
• AAALAC-accredited vivarium with GLP-compliant study execution and IACUC oversight.
• Real-time tumor monitoring via digital caliper, ultrasound, or bioluminescence imaging (BLI) with luciferase-engineered lines.
• Comprehensive endpoint packages including histopathology, immunohistochemistry, flow cytometry, and biomarker quantification.
• Dedicated project managers and study directors providing weekly updates and rapid response to protocol amendments.
• Competitive timelines with study initiation within 2--4 weeks of contract execution and final reports delivered 2--3 weeks post-termination.

Contact Us

Ready to advance your bladder cancer therapeutic program with a reliable preclinical partner? Reach out to Alfa Cytology today to discuss your BT-B xenograft model requirements, request a custom proposal, or schedule a consultation with our oncology study directors. We are committed to delivering high-quality, reproducible data that supports your next milestone. Please reach out to us today via our inquiry form or email to learn more about our BT-B Xenograft Model services.

For research use only. Not intended for any clinical use.